Encoded Therapeutics
- Health & Biotech
- South San Francisco, CA, US
- Founded 2017
- Private
- encoded.com
Develops precision genetic medicines for severe neurological disorders, led by gene therapy ETX101 for SCN1A-related epilepsy.
$275MEquity raised in 2025–20262025 — · 2026 $275M · 1 equity round
$275MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 2 sources
Earlier rounds not yet sourced. Encoded Therapeutics was founded in 2017 and raised before 9 Sep 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series FAmount$275MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 12
- GV1
- ARCH Venture Partners
- Braidwell
- Farallon Capital Management
- Illumina Ventures
- Invus
- Janus Henderson Investors
- Matrix Capital Management
- Nolan Capital
- RTW Investments
- SoftBank
- Venrock
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: GV, ARCH Venture Partners +3SambaNovaAI Infra · $1.4B in 2025–2026Shared: GV, SoftBankOMass TherapeuticsHealth · $310M in 2025–2026Shared: GV, Janus Henderson InvestorsSierraAI Apps · $1.3B in 2025–2026Shared: GVOpenEvidenceHealth · $660M in 2025–2026Shared: GVRecursive SuperintelligenceAI Labs · $650M in 2025–2026Shared: GV
Also in the South San Francisco hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Encoded Therapeutics and its logo are trademarks of their owners, used here for identification only.
